Nephros (NASDAQ:NEPH) Shares Down 0.5%

Shares of Nephros, Inc. (NASDAQ:NEPH) traded down 0.5% during trading on Monday . The stock traded as low as $1.97 and last traded at $1.99. 7,676 shares were traded during trading, a decline of 62% from the average session volume of 20,068 shares. The stock had previously closed at $2.00.

Nephros Price Performance

The firm has a fifty day simple moving average of $2.75 and a 200 day simple moving average of $2.61. The company has a market cap of $20.97 million, a price-to-earnings ratio of -13.27 and a beta of 1.31.

Nephros (NASDAQ:NEPH) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $3.25 million during the quarter. Nephros had a negative return on equity of 18.25% and a negative net margin of 11.06%.

Institutional Investors Weigh In On Nephros

A number of institutional investors have recently bought and sold shares of the business. Advisor Group Holdings Inc. boosted its stake in Nephros by 89.6% during the first quarter. Advisor Group Holdings Inc. now owns 8,674 shares of the company’s stock worth $38,000 after buying an additional 4,100 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Nephros by 3.9% during the third quarter. Vanguard Group Inc. now owns 170,712 shares of the company’s stock valued at $253,000 after acquiring an additional 6,414 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Nephros by 43.8% during the fourth quarter. Renaissance Technologies LLC now owns 32,064 shares of the company’s stock valued at $37,000 after acquiring an additional 9,764 shares during the period. Wexford Capital LP lifted its holdings in shares of Nephros by 0.4% during the first quarter. Wexford Capital LP now owns 3,663,969 shares of the company’s stock valued at $533,734,000 after acquiring an additional 13,440 shares during the period. Finally, Susquehanna International Group LLP bought a new position in shares of Nephros during the first quarter valued at $39,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.